3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
May 2024 in “Journal of Fungi” Tinea capitis in adults, especially postmenopausal Black women, needs prompt treatment with oral antifungals to avoid scarring.
June 2024 in “Journal of Clinical Oncology” The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
5 citations
,
April 2015 in “HSOA journal of clinical dermatology & therapy” Triamcinolone acetonide mesotherapy may be effective for treating patchy hair loss in alopecia areata.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
January 2024 in “Skin Research and Technology” Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The serum with microneedling device improves hair loss treatment effectively and safely.
3 citations
,
January 2018 in “Archives of Disease in Childhood” Switching to generic tacrolimus was safe, effective, and saved money.
January 2025 in “Dusunen Adam The Journal of Psychiatry and Neurological Sciences” 21 citations
,
November 2018 in “Journal of the European Academy of Dermatology and Venereology” The combination of encorafenib and binimetinib caused few skin issues.
July 2024 in “Indian Dermatology Online Journal” Tinea capitis can occur in adults and should be considered if scalp issues persist.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
January 2009 in “Yearbook of Dermatology and Dermatologic Surgery” Etanercept is safe and may help improve hidradenitis suppurativa, but more research is needed.
4 citations
,
August 2023 in “Varna Medical Forum” TECAR therapy helps with pain relief, reduces inflammation, relaxes muscles, heals tissues, and is safe and effective for many conditions.
March 2026 in “British Journal of Dermatology” Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
February 2026 in “Advanced Science” TTNPB helps turn stem cells into neural stem cells, improving depression-like behaviors in rats.
November 2025 in “Archives of Dermatological Research” Using a higher concentration of triamcinolone acetonide leads to faster hair regrowth in scalp patchy alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
1 citations
,
January 2005 in “Side effects of drugs annual” The document concluded that various dermatological treatments have different effectiveness and side effects, with some causing irritation, allergic reactions, or systemic effects.
1 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
3 citations
,
September 1989 in “Journal of Investigative Dermatology” Methyl caprate greatly increases drug absorption through the skin and is better than other enhancers.
36 citations
,
March 1989 in “British journal of dermatology/British journal of dermatology, Supplement” DPCP is more effective than tretinoin gel for treating severe alopecia.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
May 2025 in “Reactions Weekly” March 2026 in “Bioconjugate Chemistry” Peptide-based PROTACs show promise in targeting hard-to-treat proteins, especially for cancer therapy.
Baricitinib is more effective than methotrexate for severe alopecia areata.